Mustang Bio, Inc. - MBIO STOCK NEWS

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in March 2022. CEO Manuel Litchman will engage in a fireside chat at Oppenheimer’s Virtual Healthcare Conference on March 15 at 4:00 p.m. ET. Additionally, Mustang will present on-demand at H.C. Wainwright’s Gene Therapy Conference starting March 30 and participate in a panel at Cantor Fitzgerald’s Rare Disease Summit the same day. These events highlight Mustang's commitment to advancing cell and gene therapies for various diseases.

Mustang Bio (NASDAQ: MBIO) announced that an abstract regarding Phase 1 trials of its oncolytic viral and CAR T-cell therapies for glioblastoma (GBM) has been selected for a late-breaking poster presentation at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. City of Hope’s Dr. Christine Brown will present the data, highlighting the combination of MB-108 oncolytic virus and MB-101 CAR T-cell therapy, together referred to as MB-109. An Investigational New Drug application for MB-109 is anticipated later this year.

Mustang Bio (NASDAQ: MBIO) announced the completion of a $75 million long-term debt facility with Runway Growth Capital. The initial $30 million was funded upon closing, with the remaining $45 million contingent on achieving predetermined milestones. This financing is expected to enhance Mustang's financial flexibility and support multiple clinical trials in 2022. The loan will be repaid through a combination of interest-only payments followed by principal repayments over 60 months. Mustang aims to advance its cell and gene therapies targeting hematologic cancers and rare genetic diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced that clinical trial data for its PSCA CAR T-cell therapy, MB-105, has been selected for presentation at the 2022 ASCO Genitourinary Cancers Symposium. The Phase 1 trial aims to assess dose limiting toxicity and preliminary efficacy in patients with PSCA-positive mCRPC. So far, 12 patients have been treated, and results indicate the therapy is feasible with a potential anti-tumor effect. Notably, no dose limiting toxicities were observed at the 100M cell dose, while some grade 3 non-infective cystitis occurred at higher doses.

Mustang Bio (NASDAQ: MBIO) has been awarded the Bronze winner for the Central region in the Eighteenth Annual Team Massachusetts Economic Impact Awards, recognizing its significant contributions to the local economy. The company achieved job growth by adding 56 new positions since January 2020 and maintains a diverse workforce with 53% women and 26% minority employees. Mustang invested $2.5 million in a 6,000 square-foot facility expansion aimed at scaling its manufacturing of cell and gene therapies. The award ceremony is scheduled for April 7, 2022.

Mustang Bio, Inc. (NASDAQ: MBIO) announced a hold from the FDA on its IND application for MB-207, a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID). The hold is pending CMC clearance and follows an IND submission in December 2021. Mustang's MB-107, another therapy for XSCID, is in a Phase 1/2 trial for newly diagnosed infants. If approved, both therapies could receive a rare pediatric disease voucher. Mustang remains committed to advancing its clinical trials for XSCID treatments.

Mustang Bio (NASDAQ: MBIO) announced interim Phase 1/2 data on its CD20-targeted CAR T cell therapy, MB-106, for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. This data will be presented at the 2022 Tandem Meetings in Salt Lake City from February 2-6. CEO Manuel Litchman highlighted MB-106's promising efficacy and safety profile, aiming for further updates and a multicenter trial under Mustang's IND within the quarter. MB-106 is developed in collaboration with Fred Hutchinson Cancer Research Center.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in January 2022. The events include the 11th Annual LifeSci Partners Corporate Access Event (Jan 5-7), H.C. Wainwright Virtual BioConnect Conference (presentation available Jan 10), and B. Riley Securities’ Virtual Oncology Conference (fireside chat on Jan 28). Webcasts of the presentations will be accessible on Mustang's website for approximately 30 days post-event. Mustang aims to develop cell and gene therapies for various cancers and rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its inclusion in the NASDAQ Biotechnology Index® effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ and is re-ranked annually based on specific eligibility criteria, such as market capitalization and trading volume. This addition may enhance Mustang's visibility and attract greater investor interest, potentially impacting its stock performance positively. Mustang focuses on cell and gene therapies for various cancers and genetic diseases, advancing partnerships with leading medical institutions.